Overexpression of TPX2 is associated with progression and prognosis of prostate cancer

Zou,Jun; Huang,Rui‑Yan; Jiang,Fu‑Neng; Chen,De‑Xiong; Wang,Cong; Han,Zhao‑Dong; Liang,Yu‑Xiang; Zhong,Wei‑De

doi:10.3892/ol.2018.9016

Overexpression of TPX2 is associated with progression and prognosis of prostate cancer

Authors:
- Jun Zou
- Rui‑Yan Huang
- Fu‑Neng Jiang
- De‑Xiong Chen
- Cong Wang
- Zhao‑Dong Han
- Yu‑Xiang Liang
- Wei‑De Zhong
View Affiliations

Affiliations: Department of Emergency Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China, Department of Ultrasonography and Electrocardiograms, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, The Second Affiliated Hospital of South China University of Technology, Guangzhou, Guangdong 510180, P.R. China, Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: June 25, 2018 https://doi.org/10.3892/ol.2018.9016
Pages: 2823-2832
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Targeting protein for Xenopus kinesin‑like protein 2 (TPX2) activates Aurora kinase A during mitosis and targets its activity to the mitotic spindle, serving an important role in mitosis. It has been associated with different types of cancer and is considered to promote tumor growth. The aim of the present study was to explore the role of TPX2 in diagnosing prostate cancer (PCa). It was identified that TPX2 expression in PCa tissues was increased compared with benign prostate tissues. Microarray analysis demonstrated that TPX2 was positively associated with the Gleason score, tumor‑node‑metastasis (TNM) stage, clinicopathological stage, metastasis, overall survival and biochemical relapse‑free survival. In vitro studies revealed that the high expression of TPX2 in PCa cells improved proliferative, invasive and migratory abilities, and repressed apoptosis of the PCa cells, without affecting tolerance to docetaxel. The results suggested that TPX2 serves as a tumorigenesis‑promoting gene in PCa, and a potential therapeutic target for patients with PCa.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 1:7–30. 2016. View Article : Google Scholar
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 2:115–132. 2016. View Article : Google Scholar
3	Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI
4	Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M and Downs J: The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol. 172:1297–1301. 2004. View Article : Google Scholar : PubMed/NCBI
5	Zare-Mirzaie A, Balvayeh P, Imamhadi MA and Lotfi M: The frequency of latent prostate carcinoma in autopsies of over 50 years old males, the Iranian experience. Med J Islam Repub Iran. 2:73–77. 2012.
6	Du P, Kumar M, Yao Y, Xie Q, Wang J, Zhang B, Gan S, Wang Y and Wu AM: Genome-wide analysis of the TPX2 family proteins in Eucalyptus grandis. BMC Genomics. 1:9672016. View Article : Google Scholar
7	Tulu US, Fagerstrom C, Ferenz NP and Wadsworth P: Molecular requirements for kinetochore-associated microtubule formation in mammalian cells. Curr Biol. 16:536–541. 2006. View Article : Google Scholar : PubMed/NCBI
8	Shao C, Duan C, Wang J, Luan S, Gao Y, Jin D, Wang D, Li Y and Xu L: Expression of microtubule-associated protein TPX2 in human gastric carcinoma and its prognostic significance. Cancer Cell Int. 16:792016. View Article : Google Scholar : PubMed/NCBI
9	Tomii C, Inokuchi M, Takagi Y, Ishikawa T, Otsuki S, Uetake H, Kojima K and Kawano T: TPX2 expression is associated with poor survival in gastric cancer. World J Surg Oncol. 1:142017. View Article : Google Scholar
10	Yang Y, Li DP, Shen N, Yu XC, Li JB, Song Q and Zhang JH: TPX2 promotes migration and invasion of human breast cancer cells. Asian Pac J Trop Med. 12:1064–1070. 2015. View Article : Google Scholar
11	Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J and Nagino M: Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Cancer Med. 4:1091–1100. 2015. View Article : Google Scholar : PubMed/NCBI
12	Huang Y, Guo W and Kan H: TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma. Int J Mol Sci. 15:18148–18161. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y, Li D and Cai S: TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med. 11:3132013. View Article : Google Scholar : PubMed/NCBI
14	Liu Q, Yang P, Tu K, Zhang H, Zheng X and Yao Y: TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res. 26:410–417. 2014.PubMed/NCBI
15	Takahashi Y, Sheridan P, Niida A, Sawada G, Uchi R, Mizuno H, Kurashige J, Sugimachi K, Sasaki S, Shimada Y, et al: The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. Ann Oncol. 26:935–942. 2015. View Article : Google Scholar : PubMed/NCBI
16	Aushev VN, Lee E, Zhu J, Gopalakrishnan K, Li Q, Teitelbaum SL, Wetmur J, Esposti Degli D, Hernandez-Vargas H, Herceg Z, et al: Novel predictors of breast cancer survival derived from miRNA activity analysis. Clin Cancer Res. 24:581–591. 2018. View Article : Google Scholar : PubMed/NCBI
17	Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin ZY, Wu YD, Liang YX, Han ZD, Liu JC and Zhong WD: Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. Onco Targets Ther. 9:2211–2220. 2016.PubMed/NCBI
18	Zeng J, Liu W, Fan YZ, He DL and Li L: PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy. Theranostics. 8:109–123. 2018. View Article : Google Scholar : PubMed/NCBI
19	Dávila-González D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, et al: Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple-negative breast cancer. Clin Cancer Res. 24:1152–1162. 2018. View Article : Google Scholar : PubMed/NCBI
20	Garrido G and Vernos I: Non-centrosomal TPX2-dependent regulation of the aurora A kinase: Functional implications for healthy and pathological cell division. Front Oncol. 6:882016. View Article : Google Scholar : PubMed/NCBI
21	Fu J, Bian M, Xin G, Deng Z, Luo J, Guo X, Chen H, Wang Y, Jiang Q and Zhang C: TPX2 phosphorylation maintains metaphase spindle length by regulating microtubule flux. J Cell Biol. 10:373–383. 2015. View Article : Google Scholar
22	de Castro Perez I and Malumbres M: Mitotic stress and chromosomal instability in cancer: The case for TPX2. Genes Cancer. 3:721–730. 2012. View Article : Google Scholar : PubMed/NCBI
23	Gu JJ, Zhang JH, Chen HJ and Wang SS: TPX2 promotes glioma cell proliferation and invasion via activation of the AKT signaling pathway. Oncol Lett. 12:5015–5022. 2016. View Article : Google Scholar : PubMed/NCBI
24	Chen QI, Cao B, Nan N, Wang YU, Zhai XU, Li Y and Chong T: TPX2 in human clear cell renal carcinoma: Expression, function and prognostic significance. Oncol Lett. 5:3515–3521. 2016. View Article : Google Scholar
25	Vainio P, Mpindi JP, Kohonen P, Fey V, Mirtti T, Alanen KA, Perala M, Kallioniemi O and Lljin K: High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. PLoS One. 7:e398012012. View Article : Google Scholar : PubMed/NCBI
26	Lohiya V, Aragon-Ching JB and Sonpavde G: Role of chemotherapy and mechanisms of resistance to chemotherapy in metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 10 Suppl 1:S57–S66. 2016.
27	Antonarakis ES and Armstrong AJ: Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 14:192–205. 2011. View Article : Google Scholar : PubMed/NCBI
28	Yamashita S, Kohjimoto Y, Iguchi T, Koike H, Kusumoto H, Iba A, Kikkawa K, Kodama Y, Matsumura N and Hara I: Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. BMC Urol. 16:132016. View Article : Google Scholar : PubMed/NCBI
29	Wang RC, Chen X, Parissenti AM, Joy AA, Tuszynski J, Brindley DN and Wang Z: Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents. PLoS One. 12:e01824002017. View Article : Google Scholar : PubMed/NCBI
30	Pan HW, Su HH, Hsu CW, Huang GJ and Wu TT: Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer. Onco Targets Ther. 10:3531–3543. 2017. View Article : Google Scholar : PubMed/NCBI
31	Banerjee S, Singh SK, Chowdhury I, Lillard JW Jr and Singh R: Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed). 9:235–245. 2017.PubMed/NCBI